COO stock icon

Cooper Companies
COO

$94.81
1.11%
 

About: CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.

Employees: 15,000

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 9 analysts
0
News positive %
of 10 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

3,883% more repeat investments, than reductions

Existing positions increased: 478 | Existing positions reduced: 12

44% more call options, than puts

Call options by funds: $37.5M | Put options by funds: $26.1M

20% more funds holding in top 10

Funds holding in top 10: 5 [Q4 2023] → 6 (+1) [Q1 2024]

3% more capital invested

Capital invested by funds: $18.3B [Q4 2023] → $18.8B (+$559M) [Q1 2024]

9% less first-time investments, than exits

New positions opened: 74 | Existing positions closed: 81

1% less funds holding

Funds holding: 573 [Q4 2023] → 566 (-7) [Q1 2024]

4.07% less ownership

Funds ownership: 97.55% [Q4 2023] → 93.48% (-4.07%) [Q1 2024]

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$100
5%
upside
Avg. target
$114
21%
upside
High target
$125
32%
upside

9 analyst ratings

positive
89%
neutral
11%
negative
0%
Baird
Jeff Johnson
24%upside
$118
Outperform
Maintained
31 May 2024
Citigroup
Joanne Wuensch
22%upside
$116
Buy
Maintained
3 Apr 2024
Redburn Partners
Issie Kirby
32%upside
$125
Buy
Upgraded
19 Mar 2024
JP Morgan
Robbie Marcus
27%upside
$120
Overweight
Upgraded
13 Mar 2024
JP Morgan
Robbie Marcus
5%upside
$100
Neutral
Maintained
1 Mar 2024

Financial journalist opinion

Based on 10 articles about COO published over the past 30 days